Clinical trial
Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic…
NCT00377780 · Laurence J.C. van Warmerdam, Other · Terminated
Key facts
| NCT number | NCT00377780 |
|---|---|
| Title | Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer |
| Official title | Phase II Multicentre Open Label Study Evaluating the Efficacy and Safety of Liposomal Doxorubicin, Trastuzumab, Docetaxel as First-line Treatment of Patients With HER2 Positive Metastatic Breast Cancer |
| Acronym | MYOHERTAX |
| Lead sponsor | Laurence J.C. van Warmerdam, Other |
| Collaborators | Cephalon Industry Sanofi |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | Non pegylated liposomal doxorubicin, trastuzumab, docetaxel |
| Enrollment | 60 |
| Start date | Aug 1, 2006 |
| Primary completion | Aug 1, 2015 |
| Completion | Aug 1, 2015 |
| First posted | Sep 18, 2006 |
| Last update posted | Sep 23, 2015 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: